## Miravo Healthcare's Transition to Private Ownership Under Searchlight Pharma Acquisition Is Now Complete

The previously announced combination of Miravo Healthcare and Searchlight Pharma Inc. has reached its final milestone. Under the terms finalized today, Searchlight has successfully acquired all outstanding shares of Miravo Healthcare at $1.35 per share in an all-cash transaction. This move transforms Miravo Healthcare from a publicly traded entity into a privately held subsidiary within the larger Searchlight organization.

### Market Positioning and Strategic Rationale

The consolidation creates what executives describe as a powerhouse in Canadian specialty pharmaceuticals. According to IQVIA CDH sales metrics, the combined entity will rank among the top three specialty pharmaceutical companies in Canada. Searchlight's leadership emphasizes that this integration strengthens the platform's ability to execute its proven acquisition and commercialization strategy while expanding its reach across women's health, urogynecology, urology, endocrinology, and hospital specialty segments.

Mark Nawacki, President and CEO of Searchlight Pharma Inc., highlighted the significance of the moment: "This completion represents a pivotal transition for Miravo Healthcare as it joins Searchlight and operates as a private enterprise. The combined strength positions us to maintain our competitive advantage and continue delivering on our sector leadership ambitions."

### Operational Details and Shareholder Procedures

Following the transaction close, Miravo Healthcare's shares will be delisted from the TSX, and the company will initiate proceedings to cease its status as a reporting issuer across Canadian provinces. Registered shareholders must submit properly completed letters of transmittal along with share certificates to TSX Trust Company (the depositary) to receive their transaction consideration. Non-registered shareholders will receive payments through their intermediaries. The depositary can be reached toll-free at 1-800-387-0825 or via email for any transmittal questions.

### Transaction Scale and Ownership Transfer

In this acquisition, Searchlight acquired all 11,388,282 issued and outstanding shares of Miravo Healthcare, representing 100% equity ownership. Prior to this arrangement, Searchlight held no shares in the company. The transaction was structured as a straight cash deal at the predetermined rate of $1.35 per share.

### About the Organizations

**Miravo Healthcare** operates as a diversified Canadian healthcare company with international operations spanning Dublin, Ireland, and manufacturing in Varennes, Québec. Its product portfolio addresses pain, allergy, neurology, and dermatology therapeutic areas. The company maintains headquarters in Mississauga, Ontario, though it is phasing out its Québec manufacturing facility.

**Searchlight Pharma Inc.**, headquartered in Montreal, specializes in identifying, acquiring, and commercializing specialty healthcare products across multiple therapeutic domains. The firm has established itself as a focused player in the Canadian specialty pharmaceutical market through disciplined execution of its acquisition and commercialization model.

### Forward-Looking Considerations

This press release contains forward-looking statements regarding the delisting process and the company's intent to cease reporting status, made under assumptions the parties consider reasonable. These statements are subject to risks and uncertainties as outlined in Miravo Healthcare's annual information form filed on March 25, 2022 (available on SEDAR). Readers should not place undue reliance on forward-looking language contained herein, which speaks only to the date of issuance.